Paasa Logo
Basilea Pharmaceutica AG logo
BSLNSIXMarket closedOpens 9:00am CET

Basilea Pharmaceutica AG

CHF 68.70Last updated
-CHF 0.40 (0.58%)Past day
Timezone

Basilea Pharmaceutica AG (SIX: BSLN) is trading at CHF 68.70, about ₹7,967 at today's CHF/INR rate, as of 25 Sep 2026, 11:30 AM ET, down 0.58% today. Indian residents can buy Basilea Pharmaceutica from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:CHF 69.20
Previous close:CHF 69.10
Volume:17.46K

Today's low

CHF 68.30

Today's high

CHF 69.40

52 week low

CHF 44.70

52 week high

CHF 70.50

BSLN opened at CHF 69.20, closed previously at CHF 69.10, and has traded between CHF 44.70 and CHF 70.50 over the past 52 weeks.

About

Basilea Pharmaceutica AG operates as a commercial-stage biopharmaceutical enterprise, concentrating its efforts on inventing and advancing treatments to address critical unmet medical needs within the therapeutic fields of oncology and anti-infectives. Its commercialized offerings include Cresemba, an azole antifungal drug available in both intravenous and oral formulations, utilized for managing invasive aspergillosis and mucormycosis in the United States and the European Union; this drug is also advancing through Phase III clinical trials in Japan for various invasive fungal infections. The company additionally provides Zevtera, an antibiotic targeting community and hospital-acquired pneumonia, which is also undergoing Phase III clinical development for acute bacterial skin and skin structure infections, along with Staphylococcus aureus bacteremia. Beyond its current portfolio, Basilea's pipeline features Derazantinib, a small molecule inhibitor in Phase 2 clinical trials for bile duct cancer, and in Phase 1/2 trials for both bladder and stomach cancers, as well as Lisavanbulin, a novel tumor checkpoint controller drug. Established in 2000, Basilea Pharmaceutica AG maintains its corporate headquarters in Basel, Switzerland.

Country
CH
CEO
David Veitch
Exchange listed on
SIX
Industry
Biotechnology
Base currency
CHF
Full Time Employees
200
Sector
Healthcare
IPO date
25/03/2004

Key statistics

Avg. volume

38.21K

Market cap

CHF 850.28M

P/E Ratio

16.13

Price-to-sales ratio

3.44

Enterprise value

CHF 757.74M

Free cash flow yield

6.50%

Debt-to-equity ratio

0.51

Return on equity

36.06%

ROIC

20.44%

Beta

0.43

Dividend yield

0.00%

Last dividend

CHF 0.00

Financial overview

Revenue

CHF 232.40M

Earnings per share

CHF 3.29

Free cash flow

CHF 59.23M

Net profit margin

21.15%

Gross margin

87.67%

EBITDA

CHF 55.26M

Revenue growth

11.44%

Similar securities

This is not an investment recommendation

How to buy Basilea Pharmaceutica from India

Indian residents can buy Basilea Pharmaceutica shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to CHF.

  3. Search for Basilea Pharmaceutica and place an order

    Find Basilea Pharmaceutica by name or by its ticker, BSLN, and choose an order type. Basilea Pharmaceutica trades 12:30 pm – 9:00 pm IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Basilea Pharmaceutica position in CHF and INR. Basilea Pharmaceutica pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Basilea Pharmaceutica from India

Trading and taxes when buying Basilea Pharmaceutica from India

Trading and limits

Trading hours
9:00 am – 5:30 pm CET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneBasilea Pharmaceutica does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained

Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

FAQs

Can Indian residents buy Basilea Pharmaceutica stock?

Yes. Basilea Pharmaceutica (BSLN) has been listed on the SIX Swiss Exchange since 2004, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to CHF. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.

How much does one Basilea Pharmaceutica share cost in rupees?

One Basilea Pharmaceutica share is CHF 68.70 — about ₹7,967 at a CHF/INR rate of 115.97 on 24 Sep 2026. Both the Basilea Pharmaceutica price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Basilea Pharmaceutica from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

How are gains on Basilea Pharmaceutica shares taxed in India?

Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the CHF/INR rate on the purchase and the sale date, so the rupee move counts alongside the Basilea Pharmaceutica price. Paasa issues a capital-gains statement for your return.

Does Basilea Pharmaceutica pay a dividend?

No. Basilea Pharmaceutica does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Basilea Pharmaceutica from India?

The SIX Swiss Exchange trades 12:30 pm – 9:00 pm IST in Indian time. The window shifts to 1:30 pm – 10:00 pm IST when Switzerland is on standard time. Orders can only execute during that window.

Do I have to declare Basilea Pharmaceutica shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Basilea Pharmaceutica holding, its cost and its closing value.

How do I sell Basilea Pharmaceutica and bring the money back to India?

You sell during market hours (12:30 pm – 9:00 pm IST) and the proceeds settle in CHF in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.

Does the rupee rate affect what I make on Basilea Pharmaceutica?

Yes. Basilea Pharmaceutica is priced in CHF, so your rupee outcome combines the CHF move with the CHF/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.